Dagmara Hering1, Elisabeth A Lambert, Petra Marusic, Carolina Ika-Sari, Antony S Walton, Henry Krum, Paul A Sobotka, Felix Mahfoud, Michael Böhm, Gavin W Lambert, Murray D Esler, Markus P Schlaich. 1. aNeurovascular Hypertension & Kidney Disease Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia bDepartment of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland cHeart Centre Alfred Hospital dDepartment of Epidemiology & Preventive Medicine eFaculty of Medicine, Nursing and Health Sciences and Department of Physiology, Monash University, Melbourne, Victoria, Australia fDepartment of Medicine and Cardiology, Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota gMedtronic ARDIAN Inc., Mountain View, California, USA hUniversitätsklinikum des Saarlandes, Homburg/Saar, Germany.
Abstract
OBJECTIVE: Renal denervation (RDN) has been demonstrated to reduce muscle sympathetic nerve activity (MSNA) and blood pressure (BP) in patients with resistant hypertension. Whether alterations of arterial stiffness may contribute to BP-lowering effects of RDN is unknown. METHODS: We measured office BP and arterial stiffness using fingertip tonometry-derived augmentation index (EndoPAT2000) at baseline and at 3-month follow-up in 50 consecutive patients with resistant hypertension. Forty patients received RDN and 10 patients served as controls. MSNA was obtained in 20 RDN and 10 non-RDN patients. RESULTS: Baseline BP averaged 170/92 ± 19/15 mmHg (RDN) and 171/93 ± 14/8 mmHg (non-RDN) despite the use of 4.9 ± 1.9 and 4.4 ± 2.0 antihypertensive drugs, respectively. RDN significantly reduced SBP (170 ± 19 vs. 154 ± 25 mmHg; P < 0.001) and DBP (92 ± 15 vs. 84 ± 16 mmHg; P<0.001), augmentation index (30.6 ± 23.8 vs. 22.7 ± 22.4%; P=0.002), AI@75 corrected for heart rate (22.4 ± 21.6 vs. 14.4 ± 20.7; P=0.002) and MSNA (80 ± 15 vs. 71 ± 18 bursts/100 heartbeats; P<0.01). Changes in AI@75 with RDN were unrelated to SBP (r=0.043; P = 0.79), and DBP (r = 0.092; P = 0.57) and MSNA changes (r = -0.17; P = 0.49). No changes in BP, augmentation index, AI@75 or MSNA were observed in the non-RDN group. CONCLUSION: RDN results in a substantial and rapid reduction in augmentation index, which appears to be independent of BP and MSNA changes. These findings are indicative of a beneficial effect of RDN on arterial stiffness in patients with resistant hypertension and may contribute to the sustained BP-lowering effect of RDN.
OBJECTIVE: Renal denervation (RDN) has been demonstrated to reduce muscle sympathetic nerve activity (MSNA) and blood pressure (BP) in patients with resistant hypertension. Whether alterations of arterial stiffness may contribute to BP-lowering effects of RDN is unknown. METHODS: We measured office BP and arterial stiffness using fingertip tonometry-derived augmentation index (EndoPAT2000) at baseline and at 3-month follow-up in 50 consecutive patients with resistant hypertension. Forty patients received RDN and 10 patients served as controls. MSNA was obtained in 20 RDN and 10 non-RDN patients. RESULTS: Baseline BP averaged 170/92 ± 19/15 mmHg (RDN) and 171/93 ± 14/8 mmHg (non-RDN) despite the use of 4.9 ± 1.9 and 4.4 ± 2.0 antihypertensive drugs, respectively. RDN significantly reduced SBP (170 ± 19 vs. 154 ± 25 mmHg; P < 0.001) and DBP (92 ± 15 vs. 84 ± 16 mmHg; P<0.001), augmentation index (30.6 ± 23.8 vs. 22.7 ± 22.4%; P=0.002), AI@75 corrected for heart rate (22.4 ± 21.6 vs. 14.4 ± 20.7; P=0.002) and MSNA (80 ± 15 vs. 71 ± 18 bursts/100 heartbeats; P<0.01). Changes in AI@75 with RDN were unrelated to SBP (r=0.043; P = 0.79), and DBP (r = 0.092; P = 0.57) and MSNA changes (r = -0.17; P = 0.49). No changes in BP, augmentation index, AI@75 or MSNA were observed in the non-RDN group. CONCLUSION: RDN results in a substantial and rapid reduction in augmentation index, which appears to be independent of BP and MSNA changes. These findings are indicative of a beneficial effect of RDN on arterial stiffness in patients with resistant hypertension and may contribute to the sustained BP-lowering effect of RDN.
Authors: Jeanie Park; Peizhou Liao; Salman Sher; Robert H Lyles; Don D Deveaux; Arshed A Quyyumi Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-12-04 Impact factor: 3.619
Authors: Anna Pisano; Luigi Francesco Iannone; Antonio Leo; Emilio Russo; Giuseppe Coppolino; Davide Bolignano Journal: Cochrane Database Syst Rev Date: 2021-11-22
Authors: Abraham R Tzafriri; Felix Mahfoud; John H Keating; Peter M Markham; Anna Spognardi; Gee Wong; Kristine Fuimaono; Michael Böhm; Elazer R Edelman Journal: J Am Coll Cardiol Date: 2014-09-16 Impact factor: 24.094
Authors: Tatjana Kalizki; Bernhard M W Schmidt; Ulrike Raff; Annemarie Reinold; Thomas K Schwarz; Markus P Schneider; Roland E Schmieder; Andreas Schneider Journal: J Clin Hypertens (Greenwich) Date: 2017-02-17 Impact factor: 3.738
Authors: C Tsioufis; A Ziakas; K Dimitriadis; P Davlouros; M Marketou; A Kasiakogias; C Thomopoulos; D Petroglou; D Tsiachris; M Doumas; E Skalidis; C Karvounis; D Alexopoulos; P Vardas; I Kallikazaros; C Stefanadis; V Papademetriou; D Tousoulis Journal: Clin Res Cardiol Date: 2016-12-12 Impact factor: 5.460
Authors: Hitesh C Patel; Carl Hayward; Vassilis Vassiliou; Ketna Patel; James P Howard; Carlo Di Mario Journal: Integr Blood Press Control Date: 2015-12-03